title: Chemoembolization alone vs combined chemoembolization and hepatic arterial infusion chemotherapy in inoperable hepatocellular carcinoma patients.
abstract: OBJECTIVE
  To compare the efficacy and safety of chemoembolization alone or chemoembolization combined with hepatic arterial infusion chemotherapy (HAIC), including oxaliplatin (OXA), 5-fluorouracil (5-FU) and folinic acid (CF), in inoperable hepatocellular carcinoma (HCC) without distant metastasis.
  
  
  METHODS
  Eighty-four inoperable HCC patients were enrolled. Thirty-nine patients underwent chemoembolization alone, and the other 45 patients underwent chemoembolization + HAIC (OXA/5-FU/CF) treatment non-randomly. The progression free survival (PFS), objective response rate (ORR), disease control rate (DCR) and adverse reactions were compared between the two groups.
  
  
  RESULTS
  A significant difference in the ORR was observed between the chemoembolization alone and chemoembolization + HAIC groups. There was no statistically significant difference in DCR between the two groups. The median PFS (mPFS) showed a significant difference between the two groups. For patients with BCLC stage A/B disease, with or without vessel invasion, the chemoembolization + HAIC group showed better mPFS when compared to chemoembolization alone, but no significant difference was found in patients with BCLC stage C disease. The parameter of pain (grade III-IV) in the chemoembolization + HAIC group was increased statistically.
  
  
  CONCLUSIONS
  Chemoembolization combined with HAIC with OXA/5-FU/CF may be safe and more effective than chemoembolization alone for inoperable HCC patients without distant metastasis.
authors.affiliation: Song Gao, Peng-Jun Zhang, Jian-Hai Guo, Hui Chen, Hai-Feng Xu, Peng Liu, Ren-Jie Yang, Xu Zhu, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Interventional Therapy Department, Peking University Cancer Hospital & Institute, Beijing 100142, China.
authors.forename: Song
authors.initials: S
authors.lastname: Gao
authors.affiliation: Song Gao, Peng-Jun Zhang, Jian-Hai Guo, Hui Chen, Hai-Feng Xu, Peng Liu, Ren-Jie Yang, Xu Zhu, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Interventional Therapy Department, Peking University Cancer Hospital & Institute, Beijing 100142, China.
authors.forename: Peng-Jun
authors.initials: PJ
authors.lastname: Zhang
authors.affiliation: Song Gao, Peng-Jun Zhang, Jian-Hai Guo, Hui Chen, Hai-Feng Xu, Peng Liu, Ren-Jie Yang, Xu Zhu, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Interventional Therapy Department, Peking University Cancer Hospital & Institute, Beijing 100142, China.
authors.forename: Jian-Hai
authors.initials: JH
authors.lastname: Guo
authors.affiliation: Song Gao, Peng-Jun Zhang, Jian-Hai Guo, Hui Chen, Hai-Feng Xu, Peng Liu, Ren-Jie Yang, Xu Zhu, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Interventional Therapy Department, Peking University Cancer Hospital & Institute, Beijing 100142, China.
authors.forename: Hui
authors.initials: H
authors.lastname: Chen
authors.affiliation: Song Gao, Peng-Jun Zhang, Jian-Hai Guo, Hui Chen, Hai-Feng Xu, Peng Liu, Ren-Jie Yang, Xu Zhu, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Interventional Therapy Department, Peking University Cancer Hospital & Institute, Beijing 100142, China.
authors.forename: Hai-Feng
authors.initials: HF
authors.lastname: Xu
authors.affiliation: Song Gao, Peng-Jun Zhang, Jian-Hai Guo, Hui Chen, Hai-Feng Xu, Peng Liu, Ren-Jie Yang, Xu Zhu, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Interventional Therapy Department, Peking University Cancer Hospital & Institute, Beijing 100142, China.
authors.forename: Peng
authors.initials: P
authors.lastname: Liu
authors.affiliation: Song Gao, Peng-Jun Zhang, Jian-Hai Guo, Hui Chen, Hai-Feng Xu, Peng Liu, Ren-Jie Yang, Xu Zhu, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Interventional Therapy Department, Peking University Cancer Hospital & Institute, Beijing 100142, China.
authors.forename: Ren-Jie
authors.initials: RJ
authors.lastname: Yang
authors.affiliation: Song Gao, Peng-Jun Zhang, Jian-Hai Guo, Hui Chen, Hai-Feng Xu, Peng Liu, Ren-Jie Yang, Xu Zhu, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Interventional Therapy Department, Peking University Cancer Hospital & Institute, Beijing 100142, China.
authors.forename: Xu
authors.initials: X
authors.lastname: Zhu
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D006528:Carcinoma, Hepatocellular / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D016461:Chemoembolization, Therapeutic / Q000009:adverse effects / Q000401:mortality; D016009:Chi-Square Distribution; D002681:China; D018572:Disease-Free Survival; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006499:Hepatic Artery; D006801:Humans; D007261:Infusions, Intra-Arterial; D053208:Kaplan-Meier Estimate; D002955:Leucovorin / Q000008:administration & dosage; D008113:Liver Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D016016:Proportional Hazards Models; D011446:Prospective Studies; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D002955:Leucovorin; D005472:Fluorouracil
keywords: Chemoembolization; Hepatic arterial infusion chemotherapy; Hepatocellular carcinoma; Oxaliplatin